Rajaie Cardiovascular Medical and Research Center
Quick facts
Phase 3 pipeline
- intermediate dose Enoxaparin/ unfractionated heparin · Cardiovascular
Enoxaparin and unfractionated heparin work by inhibiting the coagulation cascade, specifically by activating antithrombin and inhibiting thrombin and factor Xa. - Six percent hydroxy ethyl starch 130/0.4 · Cardiovascular / Critical Care
Hydroxyethyl starch (HES) 130/0.4 is a synthetic colloid that expands intravascular volume by increasing plasma oncotic pressure and maintaining fluid in the vascular space.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Rajaie Cardiovascular Medical and Research Center portfolio CI brief
- Rajaie Cardiovascular Medical and Research Center pipeline updates RSS
Frequently asked questions about Rajaie Cardiovascular Medical and Research Center
What is Rajaie Cardiovascular Medical and Research Center's pipeline?
Rajaie Cardiovascular Medical and Research Center has 2 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include intermediate dose Enoxaparin/ unfractionated heparin, Six percent hydroxy ethyl starch 130/0.4.
Related
- Sector hub: All tracked pharma companies